- Home
- VTGN
as 07-04-2025 12:37pm EST
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 59.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 193.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $4.21 | Next Earning Date: | 08-12-2025 |
| Revenue: | $486,000 | Revenue Growth: | -54.32% |
| Revenue Growth (this year): | -9.75% | Revenue Growth (next year): | 943.32% |
Latest VistaGen Therapeutics Inc. News
VTGN Breaking Stock News: Dive into VTGN Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
Simply Wall St.
16 days ago
Vistagen Therapeutics Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag
GuruFocus.com
17 days ago
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...
Business Wire
18 days ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
GuruFocus.com
19 days ago
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For
Business Wire
23 days ago
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
Business Wire
a month ago
Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
Business Wire
a month ago
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
Compare VTGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTGN VistaGen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.